[PDF][PDF] Traitements contre la COVID-19: orientations évolutives, 3 mars 2022
O mondiale de la Santé - 2022 - apps.who.int
Plus de 418 millions de cas confirmés de COVID-19 avaient été comptabilisés au 20 février
2022 (10). La pandémie a fait jusqu'à présent environ 5, 8 millions de morts (10). Dans …
2022 (10). La pandémie a fait jusqu'à présent environ 5, 8 millions de morts (10). Dans …
[PDF][PDF] Traitements contre la COVID-19: orientations évolutives, 14 juillet 2022
O mondiale de la Santé - 2022 - iris.who.int
Plus de 524 millions de cas confirmés de COVID-19 avaient été comptabilisés en mai 2022
(10). La pandémie a fait jusqu'à présent environ 6, 2 millions de morts (10). Dans plusieurs …
(10). La pandémie a fait jusqu'à présent environ 6, 2 millions de morts (10). Dans plusieurs …
[HTML][HTML] On the Safety of the COVID-19 Convalescent Plasma Treatment: Thrombotic and Thromboembolic Concerns
F Elrashdy, EM Redwan, VN Uversky - COVID, 2021 - mdpi.com
Recently, it was reported that near-sourced COVID-19 convalescent plasma (CP) is more
efficient than distantly sourced CP. What was left behind in this analysis is the investigation …
efficient than distantly sourced CP. What was left behind in this analysis is the investigation …
Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariants
AR Mäkelä, H Uğurlu, L Hannula, R Kant, P Salminen… - bioRxiv, 2021 - biorxiv.org
The recent emergence of novel SARS-CoV-2 variants capable of efficiently escaping
neutralizing antibodies emphasizes the need for prophylactic strategies to complement …
neutralizing antibodies emphasizes the need for prophylactic strategies to complement …
[PDF][PDF] Tractament farmacològic de la infecció per SARS-CoV-2
G del Medicament - Recuperado a partir de https://canalsalut. gencat. cat …, 2020 - core.ac.uk
Per al tractament de la infecció per SARS-CoV-2, es disposa ja d'alguns assaigs clínics
controlats que permeten realitzar recomanacions basades en l'evidència. Actualment s' …
controlats que permeten realitzar recomanacions basades en l'evidència. Actualment s' …
[PDF][PDF] Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis
F Geisendörfer - 2023 - d-nb.info
Background Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-
19 course, but there are limited real-world data available on the risk associated with COVID …
19 course, but there are limited real-world data available on the risk associated with COVID …
[HTML][HTML] Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study
Background: We developed and validated a machine learning diagnostic model for novel
coronavirus (COVID-19) disease, integrating artificial-intelligence-based computed …
coronavirus (COVID-19) disease, integrating artificial-intelligence-based computed …
[HTML][HTML] Liver failure resolved via corticosteroids plus plasma exchange in a patient with hepatocellular carcinoma receiving nivolumab immunotherapy: case report
Y Gu, Y Zhang, Y Huang, Y Bi, Z Li, J Zhu - Annals of Blood, 2023 - aob.amegroups.org
Background: Therapy with immune checkpoint inhibitors (ICIs) is an option for advanced
hepatocellular carcinoma (HCC). Prednisone is recommended for immune-mediated …
hepatocellular carcinoma (HCC). Prednisone is recommended for immune-mediated …
[HTML][HTML] Methodological quality and reporting quality of COVID-19 living systematic review: a cross-sectional study
J Luo, Z Chen, D Liu, H Li, S He, L Zeng… - BMC Medical Research …, 2023 - Springer
Objectives The main objective of this study is to evaluate the methodological quality and
reporting quality of living systematic reviews (LSRs) on Coronavirus disease 2019 (COVID …
reporting quality of living systematic reviews (LSRs) on Coronavirus disease 2019 (COVID …